Messenger RNA (mRNA) News and Research

RSS

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

NuGEN Technologies launches its next generation Ovation RNA-Seq System

NuGEN Technologies, Inc., a pace-setter in genomic sample preparation, enters the next generation sequencing (NGS) market today with its Ovation RNA-Seq System, a revolutionary method of sample preparation that broadens research horizons with a more comprehensive representation of the transcriptome created from samples of a few hundred picograms.

2 Dec 2009

Cancer Genomic Microarray Facility selects febit's Geniom RT Analyzer to advance its biomedical research

The Cancer Genomic Microarray Facility at the Kimmel Cancer Center of the Thomas Jefferson University, Philadelphia, selected febit's Geniom® RT Analyzer to advance its biomedical research by proceeding targeted Next-Generation Sequencing (NGS), genome-wide single nucleotide polymorphism (SNP) and microRNA (miRNA) analysis.

2 Dec 2009

Exiqon announces the recognition of ICCB-L

Exiqon A/S announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence.

30 Nov 2009

Cells protect themselves against viruses and bacteria with novel non-genetic mechanism

When cells are confronted with an invading virus or bacteria or exposed to an irritating chemical, they protect themselves by going off their DNA recipe and inserting the wrong amino acid into new proteins to defend them against damage, scientists have discovered.

26 Nov 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

Researchers uncover atomic-level action of ring-shaped protein motors

The atomic-level action of a remarkable class of ring-shaped protein motors has been uncovered by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) using a state-of-the-art protein crystallography beamline at the Advanced Light Source (ALS).

25 Nov 2009

Direct link between insulin and core body temperature discovered

A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature. While much research has been conducted on insulin since its discovery in the 1920s, this is the first time the hormone has been connected to the fundamental process of temperature regulation.

20 Nov 2009

AcroMetrix introduces the OptiQual HPV Genotype Panel

AcroMetrix, a leading manufacturer of quality control material for clinical diagnostic and blood testing laboratories, announced today the launch of its OptiQual HPV Genotype Panel. Designed to help clinical laboratories comply with CLIA guidelines for qualitative molecular assays that detect Human Papillomavirus (HPV), this addition to AcroMetrix’s line of women’s health products can assist laboratorians with the validation and verification of their molecular HPV tests.

19 Nov 2009

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.

19 Nov 2009

Researchers identify a molecular mechanism that contributes to colorectal tumors

Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.

16 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD). The research, published by Cell Press in the November 12 issue of the journal Neuron, finds that the novel gene interacts with a key cellular enzyme previously linked with AD pathology, thereby uncovering a new strategy for treating this devastating disorder.

12 Nov 2009

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.

12 Nov 2009

Yo-yo dieting and sugar-bingeing can lead to anxiety and withdrawal symptoms

In research that sheds light on the perils of yo-yo dieting and repeated bouts of sugar-bingeing, researchers from The Scripps Research Institute have shown in animal models that cycling between periods of eating sweet and regular-tasting food can activate the brain's stress system and generate overeating, anxiety, and withdrawal-like symptoms.

10 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface.

5 Nov 2009

Pateamine A found to inhibit yet another anti-cancer mechanism

Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers in research involving this novel marine natural product.

3 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Messenger RNA (mRNA) News and Research

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

NuGEN Technologies launches its next generation Ovation RNA-Seq System

Cancer Genomic Microarray Facility selects febit's Geniom RT Analyzer to advance its biomedical research

Exiqon announces the recognition of ICCB-L

Cells protect themselves against viruses and bacteria with novel non-genetic mechanism

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Researchers uncover atomic-level action of ring-shaped protein motors

Direct link between insulin and core body temperature discovered

AcroMetrix introduces the OptiQual HPV Genotype Panel

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Researchers identify a molecular mechanism that contributes to colorectal tumors

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Study: Mouse gene uncovers new strategy for treating Alzheimer's disease

Researchers identify mouse gene that reduces the accumulation Alzheimer's plaques and tangles

Yo-yo dieting and sugar-bingeing can lead to anxiety and withdrawal symptoms

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Pateamine A found to inhibit yet another anti-cancer mechanism

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

eBook: A guide to RNA sequencing eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News